Disclosure of payments made to HCPs
We acknowledge the importance of increased transparency and of putting the patient at the centre of every decision we take. We remain committed to disclosing the payments we make to HCPs and intend to expand our reporting of payments to individual HCPs.
We already publish payments made to HCPs in 32 markets across Europe (including Russia and Ukraine) as well as Australia, Japan and the US for activities such as advisory boards, scientific symposiums and market research.
From 2019, where legally permitted, we will now report individual level payments made each year to HCPs for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.
Find out more about our payments to HCPs, click here to visit our global website.
By 2016, we have committed to end the practice of making payments to healthcare professionals (HCPs) to speak on our behalf about our medicines or vaccines to audiences who can prescribe or who can influence prescribing. We will also end the practice of providing direct financial support for individual HCPs to attend medical conferences.
In the intervening period, we will continue to disclose any payments we do make to HCPs for speaking on our behalf about products or disease areas and for attending medical conferences.
We are committed to publishing all other payments we make to HCPs. We already do so in several countries including Australia, France, Netherlands, Portugal, Slovakia, Japan, the UK and the USA, in line with locally agreed government or industry association standards.
We will continue to support and work towards transparency in other countries as industry associations or governments establish specific guidelines for disclosure - for example, through the European Federation of Pharmaceutical Industry Association (EFPIA) code on payments.
We also continue to work towards publishing global figures at an aggregate level for the payments to HCPs, for activities such as advisory services and clinical research.
Find out more about our payments to HCPs in the USA, Europe and the rest of the world via the tabs at the top of this page.
GSK was one of the first pharmaceutical companies in the USA to voluntarily disclose information about our work with physicians, including fees for speaking and consulting, which we have posted publicly since 2009. In 2010, we began disclosing payments to institutions and lead investigators for assisting with clinical research studies.
We publish the Physician Payments Report to detail our payments and other transfers of value to those US Health Care Professionals (HCPs) who we have engaged as speakers about our medicines and the conditions they are approved to treat.
These speaking events are attended by other physicians. We also detail payments to physicians who work with us as advisors to help us understand trends in the delivery of healthcare and the evolving needs of patients and providers for more effective medicines and vaccines. We report payments for reasonable expenses incurred by physician speakers and advisers while conducting programmes on our behalf, such as meals, airfare and lodging. We also report modest meals provided to physicians who attend a speaker programme or in-office presentation, and other expenses which are non-cash items of value or services, such as certain educational items.
We currently disclose information about payments we make to HCPs in a number of European countries including the UK, France, Netherlands and Slovakia.
In line with new guidance from the European Federation of Pharmaceutical Industry Association (EFPIA), we will start to disclose certain payments to doctors across 33 European countries from January 2016 for payments made during 2015.
This covers sponsoring individual HCPs to attend congresses and payments for speaking fees. Full details of the EFPIA Disclosure Code are available on the EFPIA website.
Outside of Europe and the USA, we continue to support and work towards transparency as industry associations or governments establish specific guidelines for disclosure.
We also continue to work towards publishing global figures at an aggregate level for the payments to HCPs that will continue, for activities such as advisory services and clinical research.